Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Operating Expenses (2020 - 2025)

Treace Medical Concepts' Operating Expenses history spans 6 years, with the latest figure at $56.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.15% year-over-year to $56.3 million; the TTM value through Dec 2025 reached $223.9 million, changed 0.02%, while the annual FY2025 figure was $223.9 million, 0.02% changed from the prior year.
  • Operating Expenses reached $56.3 million in Q4 2025 per TMCI's latest filing, up from $55.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $59.9 million in Q1 2024 to a low of $16.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $44.8 million, with a median of $49.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 189.47% in 2021, then decreased 4.13% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $33.7 million in 2021, then surged by 31.42% to $44.2 million in 2022, then skyrocketed by 30.01% to $57.5 million in 2023, then decreased by 3.21% to $55.7 million in 2024, then increased by 1.15% to $56.3 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Operating Expenses are $56.3 million (Q4 2025), $55.4 million (Q3 2025), and $54.7 million (Q2 2025).